Carlyle Group Inc. Invests $227,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Carlyle Group Inc. acquired a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYREFree Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,620 shares of the company’s stock, valued at approximately $227,000. Spyre Therapeutics accounts for approximately 0.0% of Carlyle Group Inc.’s holdings, making the stock its 27th biggest holding.

Other hedge funds have also bought and sold shares of the company. SG Americas Securities LLC bought a new stake in Spyre Therapeutics during the second quarter valued at $130,000. EFG Asset Management North America Corp. bought a new stake in shares of Spyre Therapeutics during the 2nd quarter valued at about $869,000. Bank of New York Mellon Corp acquired a new stake in Spyre Therapeutics during the second quarter worth approximately $2,767,000. Rhumbline Advisers bought a new stake in Spyre Therapeutics in the second quarter worth approximately $1,220,000. Finally, TD Asset Management Inc acquired a new position in Spyre Therapeutics in the second quarter valued at approximately $827,000. Institutional investors own 80.39% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on SYRE shares. Evercore ISI began coverage on shares of Spyre Therapeutics in a research report on Tuesday, July 16th. They set an “outperform” rating for the company. Wedbush assumed coverage on shares of Spyre Therapeutics in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $45.00 price target for the company. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $43.43.

Get Our Latest Analysis on SYRE

Spyre Therapeutics Trading Up 3.2 %

Spyre Therapeutics stock opened at $29.36 on Monday. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -0.41 and a beta of 2.92. The firm’s fifty day moving average price is $27.84 and its two-hundred day moving average price is $32.05. Spyre Therapeutics, Inc. has a 1-year low of $8.43 and a 1-year high of $47.97.

Spyre Therapeutics (NASDAQ:SYREGet Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.86) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.04. On average, research analysts forecast that Spyre Therapeutics, Inc. will post -3.68 EPS for the current year.

Spyre Therapeutics Company Profile

(Free Report)

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).

Further Reading

Want to see what other hedge funds are holding SYRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spyre Therapeutics, Inc. (NASDAQ:SYREFree Report).

Institutional Ownership by Quarter for Spyre Therapeutics (NASDAQ:SYRE)

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.